Inrebic is an oral kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
If you have a Hayes login, click here to view the full report on the Knowledge Center.